Bionor Pharma Announces Interim Administration
(Oslo, 25 January 2015). Reference is made to the announcement on 9 January regarding the employment of Dr. David H. Solomon as new CEO of Bionor Pharma ASA.
The permanent employment of Dr. Solomon requires a waiver under the Public Limited Liability Companies Act section 6-11 which
requires a CEO to be a Norwegian or EEA citizen. The Company expects to receive the waiver during February.
Dr. Solomon commenced the position as incoming CEO under a temporary employment contract on 19 January 2015. Former CEO Anker Lundemose stepped down from his position effective from 24 January 2015. In the interim period until the required waiver is obtained the Board has appointed CFO Synne H. Røine as Administrative Leader (Nw: daglig leder) in accordance with the PLLCA section 6-2. During the interim period Dr. Solomon will be authorised to perform all practical tasks and represent the Company as incoming CEO in cooperation with Ms. Røine and the Board of Directors.